Johnson & Johnson Diabetes Drug Endorsed by Review Panel
A panel of government advisers recommended on a 10-5 vote Thursday that Johnson & Johnson’s (NYSE:JNJ) experimental diabetes drug Invokana should be approved by the Food and Drug Administration. The vote is a win for J&J as it hopes to get clearance for its first prescription drug for diabetes. The company conducted a massive study of more than 10 000 people to show the benefits of the medicine. On a separate vote the panelists were split 8-7 on whether the company provided evidence that Invokana’s risk of heart attack stroke and other cardiovascular events is acceptable under FDA guidelines. ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here